Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: VikingWarrior who wrote (630)	7/30/1999 8:00:00 AM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

The open label extension is probably old news. I periodically checked the site for enrollment figures. Somehow I missed that an amendment to the open label period had been added. It tells you something about the no nonsense, no hype, attitude of NTII that they didn't make an announcement about this. I completely agree with your assessment that this is a major vote of confidence. The test phase is double blind, so no one knows whose getting memantine and whose getting placebo. But, in the open label phase, everyone is getting memantine. They must be noticing that it is working to want to keep taking it longer. I can't think of another logical explanation. Best regards John de C